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Abstract
PDE9 inhibitors have been studied as therapeutics for treatment of cardiovascular diseases, diabetes,
and neurodegenerative disorders. To illustrate the inhibitor selectivity, the crystal structures of the
PDE9A catalytic domain in complex with the enantiomers of PDE9 inhibitor 1-(2-chlorophenyl)-6-
(3,3,3-trifluoro-2-methylpropyl)-1H-pyrazolo[3,4-d]pyrimidine-4(5H)-one ((R)-BAY73-6691 or
(S)-BAY73-6691, 1r or 1s) were determined and mutagenesis was performed. The structures showed
that the fluoromethyl groups of 1r and 1s had different orientations while the other parts of the
inhibitors commonly interacted with PDE9A. These differences may explain the slightly different
affinity of 1r (IC50 = 22 nM) and 1s (IC50 = 88 nM). The mutagenesis experiments revealed that
contribution of the binding residues to the inhibitor sensitivity varies dramatically, from a few of
folds to three orders of magnitude. On the basis of the crystal structures, a hypothesized compound
that simulates the recently published PDE9 inhibitors was modeled to provide insight into the
inhibitor selectivity.
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The second messengers adenosine and guanosine 3′, 5′-cyclic monophosphate (cAMP and
cGMP) mediate the response of cells to a wide variety of hormones and neurotransmitters and
modulate many metabolic processes, including cardiac and smooth muscle contraction, steroid
hormone function, platelet aggregation, apotosis, leukocyte migration, adrenal hyperplasia,
inflammation, axon guidance and regeneration, memory, and circadian regulation.1–7 The
signaling of cAMP and cGMP in vivo is mainly involved in three types of enzymes: cyclases,
phosphodiesterases, and kinases. Phosphodiesterases (PDEs) are the sole enzymes hydrolyzing
cellular cyclic nucleotides and thus play pivotal roles in the physiological processes involving
the nucleotide signaling pathways. Human genome contains 21 PDE genes that are categorized
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into 11 families and encode over 100 isoforms of proteins via alternative mRNA splicing.8–
10
PDE9 was first reported in 1998 and is cGMP-specific with Km of 70 – 390 nM and Vmax of
0.96 – 4.9 μmol/min/mg.11–14 Since cGMP acts as a feed-forward mediator to enhance glucose-
stimulated insulin secretion and sensitivity and also has an anti-apoptotic effect in beta cells,
15 control on cellular cGMP would represent a new direction for treatment of diabetes. For the
specific activity of PDE9 in hydrolysis of cGMP,16–18 PDE9 selective inhibitors have been
studied as therapeutics for the treatments of the insulin-resistance syndrome,19 cardiovascular
diseases,20 type 1 and 2 diabetes,19, 21, 22 and obesity.23 More recently, for its high expression
in brain,24 PDE9 has been shown to be a potential target for treatment of memory deficits that
are associated with aging and neurodegenerative disorders such as Alzheimer’s disease.25–28
The crystal structures of PDE9A in complex with non-selective inhibitor 3-isobutyl-1-
methylxanthine (IBMX) or substrate cGMP have been reported,14, 29 but no structures of
PDE9 in complex with selective inhibitors are available. Lack of structural information is
apparently an obstacle for discovery of PDE9 inhibitors and may explain why only few PDE9
selective inhibitors are available at present.22, 30 The first published PDE9 selective inhibitor
was 1-(2-chlorophenyl)-6-(3,3,3-trifluoro-2-methylpropyl)-1H-pyrazolo[3,4-d]pyrimidine-4
(5H)-one (1, BAY73-6691, Fig. 1), which has an IC50 of 55 nM for PDE9 and shows ability
to improve learning and memory in rodents.27, 30 However, it remains unknown how inhibitor
1 selectively binds PDE9 and if one of its enantiomers is more effective than another. Reported
here are the crystal structures of the PDE9A catalytic domain in complex with the enantiomers
of 1 (1r and 1s) and the kinetics of the wild type and mutant PDE9A to provide insight into
the selectivity of PDE9 inhibitors.
Results
Structural asymmetry of two PDE9A catalytic domains in the crystals
PDE9 inhibitor 1 possesses a chiral center and thus has (R)- and (S)-enantiomeric
configurations that are respectively abbreviated as 1r and 1s (Fig. 1). The structures of the
PDE9A2 catalytic domain (residues 181–506) in complex with 1r or 1s were determined at
2.5 and 2.7 Å resolutions and refined to R-factor/R-free of 0.223/0.245 and 0.230/0.258,
respectively (Table 1). Residues 187 to 505 of these structures were traced without ambiguity.
The structures of the PDE9A2-1 complexes consist of sixteen helices and two divalent metal
ions (Fig. 2), which are folded into a topology similar to those of other PDE families.31
The asymmetric units of the PDE9A-1r/1s crystals contain two molecules of the PDE9A2
catalytic domain, the same as the previously reported structures of PDE9-IBMX and PDE9-
cGMP.14, 29 The superposition of chain A over chain B within each PDE9 structure by using
all residues yielded root-mean-squared deviations (RMSD) of 0.55, 0.60, 0.65, and 0.72 Å,
respectively for the Cα atoms of PDE9A in complex with cGMP,29 IBMX,14 1r, and 1s. When
the same chains in the different PDE9 structures were compared, the cross superposition
yielded RMSDs of 0.35 to 0.43 Å. These numbers probably indicate conformational differences
of the two molecules within the same structures. Careful examination of the structure
comparison showed that three regions at residues 432–435, 440–446, and 495–505 had
deviations larger than 2 times the average. Because residues 432–435 and 495–505 are distant
from the inhibitor binding, it is unclear whether their positional changes are due to the inhibitor
binding or the crystallographic packing. However, the movement of residues 440–446 appears
to be biologically relevant. Residues 440–446 formed a 310 helix and had the shifts of 2 to 3
times the average for their Ca atoms in the structures of PDE9A in complex with IBMX, cGMP,
1r, and 1s. The unanimous shift of the helix in all the four structures may be the consequence
of its direct interaction with the ligands. However, it is not clear if this asymmetric change of
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the fragment implicates an allosteric mechanism of the catalysis. The unliganded structure of
PDE9 is needed for further illustration.
Subtle difference in the enantiomer binding to PDE9A
The complexes of PDE9A-1r and PDE9A-1s were prepared by soaking the PDE9A-IBMX
cocrystals14 in the inhibitor solutions. Since non-selective inhibitor IBMX has very weak
affinity with PDE9A (IC50 >200 μM),12, 14 inhibitors 1r and 1s (IC50 = 22 and 88 nM,
respectively) were found to completely replace IBMX in the crystals by the soaking
experiments, as shown by the electron density (Fig. 2).
Enantiomers 1r and 1s bind to the active site of PDE9 in a similar pattern (Fig. 2). The
configurations of both enantiomers can be resolved without ambiguity, as shown by the electron
density maps of both (Fo-Fc) and (2Fo-Fc). The residues for binding of the inhibitors show
significant variation across PDE families (Table 2), implying a possibility to design PDE9
selective inhibitors. The pyrazolopyrimidine rings of 1r and 1s have common interactions with
the PDE9A residues. They stack against Phe456 and also contact via van der Waals’
interactions with residues Ile403, Asn405, and Leu420. The O4 and N5 atoms of pyrimidine
of both 1r and 1s form two hydrogen bonds with the side chain of the invariant Gln453 (Fig.
2). In addition, the chlorobenzyl groups of both enantiomers commonly contact mainly via
hydrophobic interaction with residues His252, Met365, Leu420, Tyr424, and Phe456.
However, trifluoromethyl groups of 1r and 1s show different orientations and interactions,
although they interact with the same set of residues Leu420, Leu421, Tyr424, Phe441, Ala452,
Gln453, and Phe456 (Fig. 2). Enantiomer 1s makes four and five van der Waals’ interactions
respectively with Tyr424 and Phe441, while 1r has only one and two interactions with these
residues. On the other hand, 1r makes five interactions with Leu420, but 1s has only two. These
different contacts may explain their slightly different affinity, as discussed below.
Mutagenesis reveals quantitative contribution of the binding residues
To evaluate the contribution of individual residues to the inhibitor binding, the following seven
residues that directly interact with the inhibitors were mutated to alanine: Met365, Ile403,
Leu420, Tyr424, Phe441, Gln453, and Phe456. The binding residue His252 was not studied
because His252 has been proposed to serve as a general acid for the catalysis and its mutation
would abolish the catalytic activity.29, 32 The inhibition of 1r and 1s on the catalytic activities
of wild type PDE9A2 and its mutants were measured (Table 3 and Fig. 3). The enantiomer
1s had an IC50 of 88 nM for the wild type PDE9A, which is 4 times less potent than 1r (22
nM). Among the mutants, M365A and F441A showed about 2-fold changes on inhibitory
sensitivity and thus appeared to be least important for binding of the inhibitors. The mutants
of I403A, L420A and Y424A had 6- to 9-fold changes on the IC50 values, suggesting their
moderate roles in the inhibitor binding. Most dramatic changes were produced by the mutations
of Gln453 and Phe456 to alanine, which made a loss of about three orders of magnitude of
sensitivity, indicating their important roles for inhibitor binding. However, due to the
invariance of Gln453 and the conservation of Phe456, they unlikely play critical roles in
selective recognition of inhibitors. Instead, the other binding residues that show variation across
PDE families (Table 2) should be critical for the inhibitor selectivity. For example, Tyr424
that is mutated to phenylalanine in most PDE families except for PDE8, could contribute a
unique hydroxyl group for hydrophilic interaction and would be valuable for design of PDE9
selective inhibitors. In addition, Leu420 and Ile403 that show conserved mutation to valine,
isoleucine or leucine in other PDE families (Table 2) may generate slightly different shape and
size of the binding pockets and are thus important for the inhibitor binding.
Wang et al. Page 3














PDE9 inhibitors have been shown to be potential for treatment of cardiovascular diseases, 20
type 1 and 2 diabetes,19, 21, 22 obesity,23 and neurodegenerative disorders.25–28 However, there
are only a few of PDE9 selective inhibitors published today. Lack of structural information is
apparently one of reasons for slow progress in discovery of PDE9 inhibitors. The crystal
structures of PDE9 in complex with the 1r and 1s enantiomers reveal detailed interactions of
the inhibitors, and are thus helpful with design of new PDE9 inhibitors. The structures show
that the pyrazolopyrimidine rings of the 1r and 1s enantiomers form hydrogen bonds with
Gln453 and stack against Phe456. Since these interactions are two characteristics of inhibitor
binding in almost all PDE families, 14, 33–35 the pyrazolopyrimidine ring can be taken as a
scaffold for design of new PDE9 inhibitors. In consideration of modification of
pyrazolopyrimidine, the O4 and N5 atoms of pyrimidine form two hydrogen bonds with the
invariant Gln453 in a pattern directly comparable with the binding of sildenafil and vadenafil,
35 and are thus valuable to be reserved. Among the other positions of pyrazolopyrimidine,
atoms 1 and 6 seem to be available for attachment of substitution groups because they face an
open space. An example of the design is shown in Fig. 4, and is basically equivalent to the
mother compound of the inhibitors recently reported by Pfizer’s group.22 For position #1, a
substitution group with medium size, such as an isopropyl (Fig. 4), could be attached to fit the
hydrophobic environment that is constituted with Ile403 and Met365. Since this environment
is neighbored to the metal binding pocket, a bigger substitution group with a hydrophilic atom
might be considered to interact with the hydrophilic metal pocket. In general, the substitution
at position #1 is predicted to improve the affinity of the inhibitors, but only the hydrophobic
interaction may impact the inhibitor selectivity due to variation of Met365 and Ile403 across
PDE families (Table 2).
Around position #6 is the subpocket, where the trifluoromethyl groups of the 1r and 1s
enantiomers are located but not fully occupied (Fig. 4). This pocket comprises of Leu420,
Leu421, Tyr424, Phe441, Ala452 and Gln453. Since these residues are conservatively mutated
across PDE families (Table 2), the pocket is predicted to have slightly different shapes and
sizes in the PDE families and may thus contribute to the inhibitor selectivity. This idea is
supported by the observation that the trifluoromethyl groups of the 1r and 1s enantiomers have
significantly different IC50 values although they occupy the similar pocket, and also by the
fact that the mutation of the binding residues changes inhibitor sensitivity. In consideration of
hydrophobicity and size of the pocket, a six-membered or even bigger ring could be fitted to
improve the affinity and selectivity of inhibitors. An example is a benzyl ring fitting to the
pocket (Fig. 4). It is interesting to note that the ortho-position of the modeled benzyl group,
which is marked as R in Fig. 4, orients towards the molecular surface, implying that a large
substitution group can be attached to this position. Although this prediction matches with the
series of the recently reported PDE9 inhibitors,22 the benzyl model neither perfectly fits the
pocket (Fig. 4B), nor fully uses the existence of Tyr424 that may provide a unique hydroxyl
group for the improvement of selectivity. This argument is strengthened by the observation
that the Y748F mutation of PDE8A1 increased the sensitivity of PDE8 to the inhibitors of other
PDE families.36 In short, the pocket identified by the structural and kinetic studies in this report
may be valuable for design of PDE9 selective inhibitors.
Material and Methods
Protein expression and purification of the PDE9A2 catalytic domain
The catalytic domain of the wild type human PDE9A2 (GenBank number BC009047) was
purchased from American Type Culture Collection and subcloned following the protocol
described previously.14 The coding region for expression of residues 181–506 of PDE9A2 was
amplified by PCR. The oligonucleotide primers that contain the restriction sites of NdeI and
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XhoI were designed for amplification of the desired genes of the wild type PDE9A2 and its
mutants. The amplified PDE9A2 cDNAs and the expression vector pET15b were separately
digested by the restriction enzymes NdeI and XhoI, purified with agarose gel, and then ligated
together with T4 DNA ligase.
PDE9A2 mutants of M365A, I403A, L420A, Y424A, F441A, Q453A, and F456A were
derived from pET15b-PDE9A2. Site-directed mutagenesis was carried out by following a two-
step PCR procedure. In the first round, two separate PCRs by using each primer were performed
to amplify the single-strand cDNA that contains the expression vector and the PDE9A mutant.
The products from the first round were then combined, annealed together, and amplified in the
presence of Pfu Turbo polymerase (Stratagene). The mutation products of PCR were treated
with DpnI endonuclease to eliminate the methylated parental DNA templates. All mutants were
confirmed by sequencing plasmid DNAs.
The protein purification of the wild type and mutants of PDE9A used the similar protocols as
described by Huai et al.14 Briefly, the resultant plasmids pET-PDE9As were transferred into
E. coli strain BL21 (Codonplus) for overexpression. The E. coli cells carrying pET-PDE9A
plasmids were grown in LB medium at 37°C to absorption A600 = 0.7 and then 0.1 mM
isopropyl β-D-thiogalactopyranoside was added for further growth at 15°C overnight.
Recombinant PDE9A2 was purified by the chromatographic columns of Ni-NTA affinity
(Qiagen), Q-Sepharose (GE Healthcare), and Sephacryl S300 (GE Healthcare). A typical batch
of purification yielded 20–100 mg PDE9A2 from a 2-liter cell culture. The PDE9A2 proteins
had purity greater than 95% as shown by SDS-PAGE.
Enzymatic assay
The enzymatic activities of the PDE9A2 (181–506) catalytic domain and its mutants were
assayed by incubating the enzymes with 100 μl of reaction mixture of 50 mM Tris-HCl (pH
7.8), 10 mM MgCl2, 0.5 mM DTT, and 3H-cGMP (20,000–40,000 cpm/assay, GE Healthcare)
at room temperature for 15 min. The reactions were terminated by addition of 200 μl 0.2 M
ZnSO4 and Ba(OH)2. The reaction product 3H-GMP was precipitated out while unreacted 3H-
cGMP remained in the supernatant. After centrifugation, the supernatant was added into 3.5-
ml liquid scintillation cocktail (ScintiSafe Plus™ 30%, Fisher Scientific) and the radioactivity
was measured by a LKB RackBeta 1214 counter. For measurement of IC50, 16 concentrations
of inhibitors were used in the presence of 30 nM substrate. The enzyme concentration that
hydrolyzed up to 70% cGMP was chosen for each inhibition assay. The hydrolysis rate had a
linear relationship with the enzyme concentration and the reaction time until 80% substrate
was converted to product. Each experiment was repeated three times. The IC50 values are the
concentration of inhibitors when 50% activities of the enzymes were inhibited.
Inhibitors, crystallization, and structure determination
Enantiomer 1s was purchased from Sigma-Aldrich (catalog number B3561) and 1r was a kind
gift of Bayer Healthcare, Germany. Crystals of the PDE9A2-1r and PDE9A2-1s complexes
were prepared by soaking PDE9A2-IBMX co-crystals in the buffer of 0.1 M HEPES (pH 7.5),
3.6 M sodium formate, and 2 mM 1r or 1s at 25°C for 3 days. The PDE9A2-IBMX crystals
were grown by (1) mixing 10–15 mg/mL PDE9A2 catalytic domain (amino acids 181–506)
with 2 mM IBMX in a buffer of 50 mM NaCl, 20 mM Tris. HCl (pH 7.5), 1 mM β-
mercaptoethanol, 1 mM EDTA, and (2) vapor diffusion (hanging drop) at 4°C. The protein
drops contained 2 μl PDE9A2-IBMX complex and 2 μl well buffer of 0.1 M HEPES (pH 7.5)
and 3.0 M sodium formate. The well buffer plus 20% glycerol was used as the cryo-solvent to
freeze the crystals in liquid nitrogen. Diffraction data were collected on beamline X29 at
Brookhaven National Laboratory (Table 1) and processed by program HKL.37 The structures
of PDE9A2-1r and PDE9A2-1s were solved by molecular replacement program AMoRe,38
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using the PDE9A catalytic domain14 as the initial model. The atomic model was rebuilt by
program O39 against the electron density map that was improved by the density modification
package of CCP4. The structure was refined by CNS.40
Acknowledgments
We thank beamline X29 at NSLS for collection of the diffraction data and BAYER Healthcare, Germany for inhibitor
1r. This work was supported in part by NIH GM59791 to HK, the 985 project of Science Foundation of Sun Yat-sen
University (XL), and the Offices of Biological and Environmental Research and Basic Energy Sciences of the US




(R)- and (S)-BAY73-6691 (R)- and (S)-1-(2-chlorophenyl)-6-(3,3,3-trifluoro-2-
methylpropyl)-1H-pyrazolo[3,4-d]pyrimidine-4(5H)-one
cAMP adenosine 3′, 5′-cyclic monophosphate
cGMP guanosine 3′, 5′-cyclic monophosphate
IBMX 3-isobutyl-1-methylxanthine
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Chemical structure of PDE9 inhibitor 1-(2-chlorophenyl)-6-(3,3,3-trifluoro-2-
methylpropyl)-1H-pyrazolo[3,4-d]pyrimidine-4(5H)-one (1).
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Structures of the PDE9A-1 complexes. (A) Ribbon diagram of the PDE9A2 catalytic domain.
(B) Superposition of the binding of 1r (yellow bonds) over 1s (pink bonds). The binding
residues of PDE9A (green and cyan bonds) have similar conformations. The dotted lines
represent the hydrogen bonds between Gln453 and inhibitor 1. The colors for atoms of 1 are:
orange for fluorine, green for chlorine, blue for nitrogen, and red for oxygen. (C) and (D)
Electron density for 1r and 1s. The (Fo-Fc) maps were calculated from the structures with
omission of the inhibitors and contoured at 3 sigmas.
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Inhibition of the wildtype PDE9A catalytic domain and its mutants by inhibitors 1r and 1s.
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Docking of a model compound to the active site of PDE9A. (A) A comparison of the modeled
compound (pink bonds) with 1r (green bonds). The binding residues of PDE9A are in the
golden color. The dotted lines represent the hydrogen bonds between Gln453 and O4 and N5
of the inhibitors. The small pink ball of the model compound represents a potential substitution
group that points towards the open molecular surface and could be varied to obtain the best
affinity. (B) Surface presentation of the subpocket for binding of trifluomethyl groups of 1r
and 1s. (C) Chemical structure of the model compound.
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Table 1
Statistics on diffraction data and structure refinement
Data collection PDE9-1r PDE9-1s
Space group P41212 P41212
Unit cell (a, c, Å) 103.2, 270.8 103.3, 271.1
Resolution (Å) 2.7 2.5
Total measurements 453,044 578,551
Unique reflections 41,185 51,787
Completeness (%) 100.0 (100.0)* 99.9(100.0)*
Average I/σ 12.2 (4.8)* 12.6 (4.8)*
Rmerge 0.084 (0.59)* 0.081 (0.57)*
Structure Refinement
R-factor 0.230 0.223
R-free 0.258 (10.0%)‡ 0.245
Resolution (Å) 15–2.7 15–2.5
Reflections 39,257 49,441
RMS deviation for
Bond 0.007 Å 0.007
Angle 1.3° 1.2°
Average B-factor (Å2)
 Protein 57.4 (5264)§ 51.5 (5288)
 Inhibitor 45.7 (48) 44.9 (48)
 Zn 46.0 (2) 53.5 (2)
 Mg 43.5 (2) 37.6 (2)
 Water 39.7 (16) 36.2 (16)
*
The numbers in parentheses are for the highest resolution shell.
‡
The percentage of reflections omitted for calculation of R-free.
§
The number of atoms in the crystallographic asymmetric unit.
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Table 3
Inhibition of PDE9 and its mutants by inhibitors 1r and 1s







F441A 129±9 43 ± 1
I403A 519±26 200±25
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